DE60220512T2 - Verwendung von flumazenil zur herstellung eines medikaments für die behandlung von kokainabhängigkeit - Google Patents

Verwendung von flumazenil zur herstellung eines medikaments für die behandlung von kokainabhängigkeit Download PDF

Info

Publication number
DE60220512T2
DE60220512T2 DE60220512T DE60220512T DE60220512T2 DE 60220512 T2 DE60220512 T2 DE 60220512T2 DE 60220512 T DE60220512 T DE 60220512T DE 60220512 T DE60220512 T DE 60220512T DE 60220512 T2 DE60220512 T2 DE 60220512T2
Authority
DE
Germany
Prior art keywords
flumazenil
treatment
cocaine
administration
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60220512T
Other languages
German (de)
English (en)
Other versions
DE60220512D1 (de
Inventor
Juan Jose Legarda Ibanez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Catasys Inc
Original Assignee
Catasys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catasys Inc filed Critical Catasys Inc
Application granted granted Critical
Publication of DE60220512D1 publication Critical patent/DE60220512D1/de
Publication of DE60220512T2 publication Critical patent/DE60220512T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
DE60220512T 2001-02-15 2002-02-08 Verwendung von flumazenil zur herstellung eines medikaments für die behandlung von kokainabhängigkeit Expired - Lifetime DE60220512T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200100342 2001-02-15
ES200100342 2001-02-15
PCT/ES2002/000061 WO2002064213A1 (es) 2001-02-15 2002-02-08 Empleo de flumazenilo en la elaboracion de un medicamento para el tratamiento de la dependencia de cocaina

Publications (2)

Publication Number Publication Date
DE60220512D1 DE60220512D1 (de) 2007-07-19
DE60220512T2 true DE60220512T2 (de) 2008-02-07

Family

ID=8496743

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60220512T Expired - Lifetime DE60220512T2 (de) 2001-02-15 2002-02-08 Verwendung von flumazenil zur herstellung eines medikaments für die behandlung von kokainabhängigkeit

Country Status (20)

Country Link
US (2) US7186711B2 (https=)
EP (1) EP1378267B1 (https=)
JP (2) JP4272885B2 (https=)
KR (1) KR100712571B1 (https=)
CN (1) CN1327843C (https=)
AT (1) ATE363923T1 (https=)
AU (1) AU2002231811B2 (https=)
BR (1) BR0207866A (https=)
CA (1) CA2436511C (https=)
CY (1) CY1106845T1 (https=)
DE (1) DE60220512T2 (https=)
DK (1) DK1378267T3 (https=)
ES (1) ES2287255T3 (https=)
IL (1) IL157144A0 (https=)
MX (1) MXPA03007281A (https=)
NZ (1) NZ528164A (https=)
PT (1) PT1378267E (https=)
RU (1) RU2322985C2 (https=)
UA (1) UA79586C2 (https=)
WO (1) WO2002064213A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050192271A1 (en) * 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
CA2436511C (en) * 2001-02-15 2009-08-04 Juan Jose Legarda Ibanez Use of flumazenil to produce a medicament for the treatment of cocaine dependency
JP2008538748A (ja) 2005-04-07 2008-11-06 ハイシアム， インコーポレイテッド 不安、物質乱用及び依存の予防のための改良型方法及び組成物
US7855196B2 (en) 2005-08-22 2010-12-21 Pierre Mainville Composition comprising a benzodiazepine agonist and a benzodiazepine antagonist
ES2289935B1 (es) * 2006-07-14 2008-12-16 Juan Jose Legarda Ibañez Empleo de flumazenilo en la elaboracion de un medicamento para el tratamiento de la patologia depresiva.
US20110034442A1 (en) * 2007-08-08 2011-02-10 Jaun Jose Legarda Ibanez Use and Methods of Use for an Antagonist of the Serotin3 Receptor (5-HT3) and a Selective Modulator of Chloride Channels for the Treatment of Addiction to or Dependence on Medicines/Drugs or Nervous System Disorders
US9396280B2 (en) * 2008-06-23 2016-07-19 Microsoft Technology Licensing, Llc Command driven web site browsing
ES2702848T3 (es) 2011-02-23 2019-03-05 Coeruleus Ltd Complejos de flumazenil, composiciones que los comprenden y usos de los mismos
US9308616B2 (en) 2013-01-21 2016-04-12 Innovative Finishes LLC Refurbished component, electronic device including the same, and method of refurbishing a component of an electronic device
WO2015054730A1 (en) * 2013-10-14 2015-04-23 Palmaya Pty Ltd Compositions and methods of administering same
CN107115359A (zh) * 2016-02-24 2017-09-01 郑恩哲 阻断海洛因或吗啡毒品中毒路径的点滴处方及其应用
EP3661500B1 (en) 2017-07-31 2026-01-07 Novartis AG Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028611A (en) * 1989-06-29 1991-07-02 The Regents Of The University Of Minnesota Treatment for cocaine use
SE9100860D0 (sv) * 1991-03-22 1991-03-22 Kabi Pharmacia Ab New use
US5229120A (en) * 1992-02-05 1993-07-20 Devincent James F Treatment for cocaine abuse
GB9225859D0 (en) * 1992-12-11 1993-02-03 Smithkline Beecham Plc Novel treatment
GB9420010D0 (en) 1994-10-01 1994-11-16 Marck Sharp & Dohme Limited Nucleic acids
EP1133299A1 (en) * 1998-11-23 2001-09-19 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
EP1125579A3 (en) * 2000-01-18 2003-01-02 Pfizer Products Inc. Uses of agrp-melanocortin receptor binding modulating compounds
CA2436511C (en) 2001-02-15 2009-08-04 Juan Jose Legarda Ibanez Use of flumazenil to produce a medicament for the treatment of cocaine dependency
US6740677B2 (en) 2002-08-19 2004-05-25 Hong Xue Methods of treating benzodiazepine site (BZD-S) associated syndromes using 2′ hydroxyflavonoids

Also Published As

Publication number Publication date
KR100712571B1 (ko) 2007-05-02
HK1061817A1 (en) 2004-10-08
EP1378267B1 (en) 2007-06-06
PT1378267E (pt) 2007-09-11
NZ528164A (en) 2006-03-31
ATE363923T1 (de) 2007-06-15
US20070142364A1 (en) 2007-06-21
WO2002064213A1 (es) 2002-08-22
DK1378267T3 (da) 2007-10-08
JP2008201799A (ja) 2008-09-04
MXPA03007281A (es) 2005-01-25
DE60220512D1 (de) 2007-07-19
JP4272885B2 (ja) 2009-06-03
AU2002231811B2 (en) 2006-02-16
KR20040010592A (ko) 2004-01-31
CN1491125A (zh) 2004-04-21
CA2436511A1 (en) 2002-08-22
RU2322985C2 (ru) 2008-04-27
US20060122219A1 (en) 2006-06-08
IL157144A0 (en) 2004-02-08
RU2003127718A (ru) 2005-01-27
US7186711B2 (en) 2007-03-06
EP1378267A1 (en) 2004-01-07
BR0207866A (pt) 2004-03-23
CN1327843C (zh) 2007-07-25
JP2004521904A (ja) 2004-07-22
CY1106845T1 (el) 2012-05-23
UA79586C2 (en) 2007-07-10
ES2287255T3 (es) 2007-12-16
CA2436511C (en) 2009-08-04

Similar Documents

Publication Publication Date Title
DE69805202T2 (de) Verwendung von benzhydrylsulfinylderivaten zur behandlung der schläfigkeit medikamentösen ursprungs
DE69900249T2 (de) Pharmazeutische zusammensetzung von metformin und fibrat, und ihre verwendung zur behandlung von hyperglykämie
DE69715899T2 (de) Zusammensetzungen zur behandlung der peripheren neuropathie, die antidepressiven verbindungen und/oder monoamino-oxidaseinhibitoren und/oder vitamin b12 und/oder neurotransmitter-vorläufer oder induktoren enthalten
DE69528773T2 (de) Behandlung von multipler sklerose (ms) und anderen demyelinisationserkrankungen unter verwendung von lofepramin in kombination mit l-phenylalamin, tyrosin oder tryptophan und evtl. einer vitamin b12-verbindung
DE69325393T2 (de) Pharmazeutische zusammensetzungen und verfahren unter verwendung von isobutyramid zur behandlung von betaglobinerkrankungen
DE69831000T2 (de) Verwendung von cytidin und cytosin-enthaltenden verbindungen zur behandlung von reizmittelgelgebrauch
DE102007009888A1 (de) Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
DE69432905T2 (de) Verwendung von ketoconazol und verwandten substanzen in medikamenten für die behandlung des typ ii-diabetes
DE69232016T2 (de) Pharmazeutische zusammensetzung, die gamma-hydroxybuttersäure oder das entsprechende lakton enthält, zur behandlung von drogenabhängigkeit und ernährungsstörungen
DE60220512T2 (de) Verwendung von flumazenil zur herstellung eines medikaments für die behandlung von kokainabhängigkeit
DE2934718A1 (de) Loesung fuer die intravenoese verabreichung
DE60214527T2 (de) Verwendung von flumazenil bei der entwicklung eines arzneimittels zur behandlung von alkoholabhängigkeit
US20030224072A1 (en) Topical and oral administration of a composition containing Pelargonium Graveolens for diagnosis and treatment of various neuralgias and other conditions
DE69821498T2 (de) Verwendung von amifostin
EP1513533A2 (de) Pharmazeutische wirkstoffkombination sowie deren verwendung
DE3643119A1 (de) Therapeutische zusammensetzung fuer diabetes-komplikationen
DE60206169T2 (de) Kombination enthaltend einen p-gp hemmer und einen antiepileptischen wirkstoff
DE69129693T2 (de) Verwendung von nickel und bromide ionen für die behandlung von psoriasis
DE69303305T2 (de) Mittel zur Behandlung chronischer Ermüdungserscheinungen
DE69308762T2 (de) Behandlung des Muskulschwunds
DE10163667B4 (de) Verwendung von Desoxypeganin zur Behandlung der klinischen Depression
DE19941217A1 (de) Behandlung der Migräne durch Verabreichung von alpha-Liponsäure oder Derivaten derselben
DE69821970T2 (de) Verwendung von CITICOLINE ZUR BEHANDLUNG VON MULTIPLER SKLEROSE
DE69205307T2 (de) Vorrichtung zum Behandeln von Akupunkturpunkten mittels elektrischen Feldern und Medikamentenionen.
DE60006284T2 (de) Arzneimittel zur behandlung konvulsivischer zustände

Legal Events

Date Code Title Description
8364 No opposition during term of opposition